{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:28:46Z","timestamp":1787074126265,"version":"build-2736575974"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05229-5","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:03:53Z","timestamp":1787069033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in the clinical application of mesenchymal stem cells for neurological disorders"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-0610","authenticated-orcid":false,"given":"Mohammad Chand","family":"Jamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-3611","authenticated-orcid":false,"given":"Alaa","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4934-2610","authenticated-orcid":false,"given":"Ali Jaber","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8112-7633","authenticated-orcid":false,"given":"Rithab Ibrahim","family":"Al-Samawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Mesfer","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4579-2921","authenticated-orcid":false,"given":"Amal Adnan","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-3093","authenticated-orcid":false,"given":"Mohammed Fareed","family":"Felemban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Mansuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-198X","authenticated-orcid":false,"given":"Faris J.","family":"Tayeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irshad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Mudhafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Ahmed","family":"Sheweita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"5229_CR1","doi-asserted-by":"crossref","unstructured":"Lamptey RNL et al. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851.","DOI":"10.3390\/ijms23031851"},{"issue":"5","key":"5229_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Global","year":"2019","unstructured":"Global. regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"key":"5229_CR3","doi-asserted-by":"crossref","unstructured":"Hans Rudolf W, Stefano Di S. Current perspectives on neurological diseases: experimental models, mechanisms of disease and treatments. CNS Neurol Disorders Drug Targets. 2020;19(8):558\u2013559.","DOI":"10.2174\/187152731908201023111147"},{"key":"5229_CR4","doi-asserted-by":"crossref","unstructured":"Kim ME, Lee JS. Mechanisms and emerging regulators of neuroinflammation: exploring new therapeutic strategies for neurological disorders. Curr Issues Mol Biol. 2024;47(1):8.","DOI":"10.3390\/cimb47010008"},{"issue":"1","key":"5229_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s40001-024-01987-1","volume":"29","author":"R Rahimi Darehbagh","year":"2024","unstructured":"Rahimi Darehbagh R, et al. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024;29(1):386.","journal-title":"Eur J Med Res"},{"issue":"1","key":"5229_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","volume":"15","author":"UC Dash","year":"2025","unstructured":"Dash UC, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B. 2025;15(1):15\u201334.","journal-title":"Acta Pharm Sin B"},{"key":"5229_CR7","doi-asserted-by":"publisher","first-page":"102921","DOI":"10.1016\/j.arr.2025.102921","volume":"113","author":"A Pithakumar","year":"2026","unstructured":"Pithakumar A, et al. From pathogenesis to precision medicine: Targeting immune imbalance in multiple sclerosis. Ageing Res Rev. 2026;113:102921.","journal-title":"Ageing Res Rev"},{"key":"5229_CR8","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.3390\/ijms26125782","volume":"26","author":"S Castelli","year":"2025","unstructured":"Castelli S, Carinci E. Baldelli Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health. Int J Mol Sci. 2025;26:5782. https:\/\/doi.org\/10.3390\/ijms26125782.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5229_CR9","doi-asserted-by":"publisher","first-page":"151097","DOI":"10.1016\/j.ejcb.2020.151097","volume":"99","author":"A Shariati","year":"2020","unstructured":"Shariati A, et al. Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier. Eur J Cell Biol. 2020;99(6):151097.","journal-title":"Eur J Cell Biol"},{"issue":"1","key":"5229_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-9-12","volume":"9","author":"R Hass","year":"2011","unstructured":"Hass R, et al. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Communication Signal. 2011;9(1):12.","journal-title":"Cell Communication Signal"},{"key":"5229_CR11","doi-asserted-by":"crossref","unstructured":"Zhang X et al. MSC-based cell therapy in neurological diseases: a concise review of the literature in pre-clinical and clinical research. Biomolecules. 2024;14(5):538.","DOI":"10.3390\/biom14050538"},{"issue":"1","key":"5229_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-021-01037-x","volume":"14","author":"T Zhou","year":"2021","unstructured":"Zhou T, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24.","journal-title":"J Hematol Oncol"},{"key":"5229_CR13","doi-asserted-by":"publisher","first-page":"176719","DOI":"10.1016\/j.ejphar.2024.176719","volume":"977","author":"J Pharoun","year":"2024","unstructured":"Pharoun J, et al. Mesenchymal stem cells biological and biotechnological advances: Implications for clinical applications. Eur J Pharmacol. 2024;977:176719.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5229_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12967-024-05294-5","volume":"22","author":"S Chen","year":"2024","unstructured":"Chen S, Liang B, Xu J. Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations. J Translational Med. 2024;22(1):459.","journal-title":"J Translational Med"},{"issue":"2","key":"5229_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00007890-196803000-00009","volume":"6","author":"AJ Friedenstein","year":"1968","unstructured":"Friedenstein AJ, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230\u201347.","journal-title":"Transplantation"},{"issue":"5","key":"5229_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","volume":"9","author":"AI Caplan","year":"1991","unstructured":"Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641\u201350.","journal-title":"J Orthop Res"},{"issue":"10","key":"5229_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","volume":"21","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan S, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019\u201324.","journal-title":"Cytotherapy"},{"key":"5229_CR18","doi-asserted-by":"publisher","first-page":"p6726185","DOI":"10.1155\/2018\/6726185","volume":"2018","author":"J Steens","year":"2018","unstructured":"Steens J. D <>Klein 2018 Current Strategies to Generate Human Mesenchymal Stem Cells In Vitro. Stem Cells Int 2018 p6726185.","journal-title":"Stem Cells Int"},{"key":"5229_CR19","doi-asserted-by":"crossref","unstructured":"Beeravolu N et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta. J Vis Exp. 2017;(122).","DOI":"10.3791\/55224-v"},{"key":"5229_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fbioe.2020.00043","volume":"8","author":"A Hmadcha","year":"2020","unstructured":"Hmadcha A, et al. Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020;8:43.","journal-title":"Front Bioeng Biotechnol"},{"key":"5229_CR21","doi-asserted-by":"publisher","first-page":"156699","DOI":"10.1016\/j.cyto.2024.156699","volume":"182","author":"Y-k Chen","year":"2024","unstructured":"Chen Y-k, et al. The role of mesenchymal stem cells in the treatment and pathogenesis of psoriasis. Cytokine. 2024;182:156699.","journal-title":"Cytokine"},{"key":"5229_CR22","doi-asserted-by":"publisher","first-page":"155422","DOI":"10.1016\/j.prp.2024.155422","volume":"260","author":"AH Mohamed","year":"2024","unstructured":"Mohamed AH, et al. Mesenchymal stem cells and their potential therapeutic benefits and challenges in the treatment and pathogenesis of gastric cancer. Pathol Res Pract. 2024;260:155422.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"5229_CR23","doi-asserted-by":"publisher","first-page":"e3962","DOI":"10.1002\/cbf.3962","volume":"42","author":"MJ Saadh","year":"2024","unstructured":"Saadh MJ, et al. Dual role of mesenchymal stem\/stromal cells and their cell-free extracellular vesicles in colorectal cancer. Cell Biochem Funct. 2024;42(2):e3962.","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"5229_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12935-021-01836-9","volume":"21","author":"S Aravindhan","year":"2021","unstructured":"Aravindhan S, et al. Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature. Cancer Cell Int. 2021;21(1):158.","journal-title":"Cancer Cell Int"},{"key":"5229_CR25","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.tice.2024.102415","volume":"89","author":"AA Patel","year":"2024","unstructured":"Patel AA, et al. Application of mesenchymal stem cells derived from the umbilical cord or Wharton\u2019s jelly and their extracellular vesicles in the treatment of various diseases. Tissue Cell. 2024;89:102415.","journal-title":"Tissue Cell"},{"issue":"1","key":"5229_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13287-024-04127-y","volume":"16","author":"W-C Huang","year":"2025","unstructured":"Huang W-C, et al. Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials. Stem Cell Res Ther. 2025;16(1):3.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-024-03940-9","volume":"15","author":"S Lai","year":"2024","unstructured":"Lai S, Guo Z. Stem cell therapies for chronic obstructive pulmonary disease: mesenchymal stem cells as a promising treatment option. Stem Cell Res Ther. 2024;15(1):312.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13287-025-04167-y","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, et al. Pyroptosis: candidate key targets for mesenchymal stem cell-derived exosomes for the treatment of bone-related diseases. Stem Cell Res Ther. 2025;16(1):68.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR29","doi-asserted-by":"publisher","first-page":"597652","DOI":"10.1155\/2015\/597652","volume":"2015","author":"F Perdisa","year":"2015","unstructured":"Perdisa F, et al. Adipose-Derived Mesenchymal Stem Cells for the Treatment of Articular Cartilage: A Systematic Review on Preclinical and Clinical Evidence. Stem Cells Int. 2015;2015:597652.","journal-title":"Stem Cells Int"},{"issue":"1","key":"5229_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13287-021-02524-1","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Yang L. Mesenchymal stem cell-derived extracellular vesicles in therapy against fibrotic diseases. Stem Cell Res Ther. 2021;12(1):435.","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"5229_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bmt.1705757","volume":"40","author":"AM Parr","year":"2007","unstructured":"Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 2007;40(7):609\u201319.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"5229_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/157488811794480744","volume":"6","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, et al. Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? Curr Stem Cell Res Ther. 2011;6(1):69\u201372.","journal-title":"Curr Stem Cell Res Ther"},{"key":"5229_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/biology15100794","volume":"15","author":"T Nurlybek","year":"2026","unstructured":"Nurlybek T, et al. Immunomodulatory Mechanisms of Mesenchymal Stromal Cells: Cytokine Networks and Therapeutic Potential Across Immune-Mediated, Inflammatory, and Regenerative Disorders. Biology. 2026;15:794. https:\/\/doi.org\/10.3390\/biology15100794.","journal-title":"Biology"},{"issue":"1","key":"5229_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-025-02313-9","volume":"10","author":"X Han","year":"2025","unstructured":"Han X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Therapy. 2025;10(1):262.","journal-title":"Signal Transduct Target Therapy"},{"issue":"10","key":"5229_CR35","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838\u201343.","journal-title":"Blood"},{"issue":"1","key":"5229_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0301-472X(01)00769-X","volume":"30","author":"A Bartholomew","year":"2002","unstructured":"Bartholomew A, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42\u20138.","journal-title":"Exp Hematol"},{"issue":"10","key":"5229_CR37","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1182\/blood-2003-04-1193","volume":"102","author":"F Djouad","year":"2003","unstructured":"Djouad F, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003;102(10):3837\u201344.","journal-title":"Blood"},{"key":"5229_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.biomaterials.2014.11.020","volume":"41","author":"MD Swartzlander","year":"2015","unstructured":"Swartzlander MD, et al. Immunomodulation by mesenchymal stem cells combats the foreign body response to cell-laden synthetic hydrogels. Biomaterials. 2015;41:79\u201388.","journal-title":"Biomaterials"},{"issue":"3","key":"5229_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/asj\/sjv231","volume":"36","author":"G Rigotti","year":"2016","unstructured":"Rigotti G, et al. Expanded Stem Cells, Stromal-Vascular Fraction, and Platelet-Rich Plasma Enriched Fat: Comparing Results of Different Facial Rejuvenation Approaches in a Clinical Trial. Aesthet Surg J. 2016;36(3):261\u201370.","journal-title":"Aesthet Surg J"},{"issue":"5","key":"5229_CR40","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21012","volume":"52","author":"F Djouad","year":"2005","unstructured":"Djouad F, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor \u03b1 in collagen-induced arthritis. Arthr Rhuem. 2005;52(5):1595\u2013603.","journal-title":"Arthr Rhuem"},{"issue":"8","key":"5229_CR41","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1600-6143.2009.02721.x","volume":"9","author":"W Ge","year":"2009","unstructured":"Ge W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transpl. 2009;9(8):1760\u201372.","journal-title":"Am J Transpl"},{"issue":"4","key":"5229_CR42","doi-asserted-by":"publisher","first-page":"e10088","DOI":"10.1371\/journal.pone.0010088","volume":"5","author":"RS Waterman","year":"2010","unstructured":"Waterman RS, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE. 2010;5(4):e10088.","journal-title":"PLoS ONE"},{"issue":"2","key":"5229_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/157488811795495486","volume":"6","author":"A Scuteri","year":"2011","unstructured":"Scuteri A, et al. Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair? Curr Stem Cell Res Ther. 2011;6(2):82\u201392.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"1","key":"5229_CR44","doi-asserted-by":"publisher","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","volume":"7","author":"F Gao","year":"2016","unstructured":"Gao F, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7(1):e2062.","journal-title":"Cell Death Dis"},{"issue":"3","key":"5229_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41583-020-0263-9","volume":"21","author":"AD Greenhalgh","year":"2020","unstructured":"Greenhalgh AD, David S, Bennett FC. Immune cell regulation of glia during CNS injury and disease. Nat Rev Neurosci. 2020;21(3):139\u201352.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"5229_CR46","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s10753-020-01230-z","volume":"43","author":"M Shao","year":"2020","unstructured":"Shao M, et al. Exosomes from Long Noncoding RNA-Gm37494-ADSCs Repair Spinal Cord Injury via Shifting Microglial M1\/M2 Polarization. Inflammation. 2020;43(4):1536\u201347.","journal-title":"Inflammation"},{"key":"5229_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1742-2094-10-106","volume":"10","author":"R Zhang","year":"2013","unstructured":"Zhang R, et al. Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation. 2013;10:106.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"5229_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5966\/sctm.2015-0065","volume":"5","author":"DJ Kota","year":"2016","unstructured":"Kota DJ, et al. Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury. Stem Cells Transl Med. 2016;5(1):33\u201344.","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"5229_CR49","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.032","volume":"23","author":"N Gu","year":"2014","unstructured":"Gu N, et al. Anti-inflammatory and antiapoptotic effects of mesenchymal stem cells transplantation in rat brain with cerebral ischemia. J Stroke Cerebrovasc Dis. 2014;23(10):2598\u2013606.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"5229_CR50","doi-asserted-by":"publisher","first-page":"634","DOI":"10.5966\/sctm.2016-0071","volume":"6","author":"FG Teixeira","year":"2017","unstructured":"Teixeira FG, et al. Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson\u2019s Disease. Stem Cells Transl Med. 2017;6(2):634\u201346.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"5229_CR51","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12015-021-10321-9","volume":"18","author":"HC Campos","year":"2022","unstructured":"Campos HC, et al. Distinct Effects of the Hippocampal Transplantation of Neural and Mesenchymal Stem Cells in a Transgenic Model of Alzheimer\u2019s Disease. Stem Cell Rev Rep. 2022;18(2):781\u201391.","journal-title":"Stem Cell Rev Rep"},{"key":"5229_CR52","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3389\/fimmu.2019.02249","volume":"10","author":"C Gavin","year":"2019","unstructured":"Gavin C, et al. The Complement System Is Essential for the Phagocytosis of Mesenchymal Stromal Cells by Monocytes. Front Immunol. 2019;10:2249.","journal-title":"Front Immunol"},{"key":"5229_CR53","doi-asserted-by":"crossref","unstructured":"Gavasso S et al. The therapeutic mechanisms of mesenchymal stem cells in ms-a review focusing on neuroprotective properties. Int J Mol Sci. 2024;25(3):1365.","DOI":"10.3390\/ijms25031365"},{"issue":"7","key":"5229_CR54","doi-asserted-by":"publisher","first-page":"2002944","DOI":"10.1002\/advs.202002944","volume":"8","author":"A Andrzejewska","year":"2021","unstructured":"Andrzejewska A, et al. Mesenchymal Stem Cells for Neurological Disorders. Adv Sci (Weinh). 2021;8(7):2002944.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"5229_CR55","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4252\/wjsc.v13.i7.776","volume":"13","author":"A Nasirishargh","year":"2021","unstructured":"Nasirishargh A, et al. Exosomal microRNAs from mesenchymal stem\/stromal cells: Biology and applications in neuroprotection. World J Stem Cells. 2021;13(7):776\u201394.","journal-title":"World J Stem Cells"},{"issue":"1","key":"5229_CR56","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.expneurol.2005.10.029","volume":"198","author":"L Crigler","year":"2006","unstructured":"Crigler L, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006;198(1):54\u201364.","journal-title":"Exp Neurol"},{"issue":"1","key":"5229_CR57","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41598-017-03592-1","volume":"7","author":"LF Martins","year":"2017","unstructured":"Martins LF, et al. Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Sci Rep. 2017;7(1):4153.","journal-title":"Sci Rep"},{"issue":"1\u20132","key":"5229_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11010-020-03727-5","volume":"469","author":"Q Bai","year":"2020","unstructured":"Bai Q, et al. NGF mediates protection of mesenchymal stem cells-conditioned medium against 2,5-hexanedione-induced apoptosis of VSC4.1 cells via Akt\/Bad pathway. Mol Cell Biochem. 2020;469(1\u20132):53\u201364.","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"5229_CR59","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1634\/stemcells.2005-0614","volume":"24","author":"FJ Rivera","year":"2006","unstructured":"Rivera FJ, et al. Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells. 2006;24(10):2209\u201319.","journal-title":"Stem Cells"},{"issue":"3","key":"5229_CR60","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1471-4159.2008.05674.x","volume":"107","author":"FJ Rivera","year":"2008","unstructured":"Rivera FJ, et al. Oligodendrogenesis of adult neural progenitors: differential effects of ciliary neurotrophic factor and mesenchymal stem cell derived factors. J Neurochem. 2008;107(3):832\u201343.","journal-title":"J Neurochem"},{"key":"5229_CR61","doi-asserted-by":"crossref","unstructured":"Alvites R et al. Mesenchymal stem\/stromal cells and their paracrine activity-immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics. 2022;14(2):381.","DOI":"10.3390\/pharmaceutics14020381"},{"key":"5229_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jare.2024.05.004","volume":"70","author":"CM Trigo","year":"2025","unstructured":"Trigo CM, et al. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? J Adv Res. 2025;70:103\u201324.","journal-title":"J Adv Res"},{"key":"5229_CR63","doi-asserted-by":"crossref","unstructured":"Eleuteri S, Fierabracci A. Insights into the secretome of mesenchymal stem cells and its potential applications. Int J Mol Sci. 2019;20(18):4597.","DOI":"10.3390\/ijms20184597"},{"issue":"1","key":"5229_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12964-020-00650-6","volume":"18","author":"K Asgarpour","year":"2020","unstructured":"Asgarpour K, et al. Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal. 2020;18(1):149.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"5229_CR65","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1038\/s41598-021-85306-2","volume":"11","author":"S Shirazi","year":"2021","unstructured":"Shirazi S, et al. The importance of cellular and exosomal miRNAs in mesenchymal stem cell osteoblastic differentiation. Sci Rep. 2021;11(1):5953.","journal-title":"Sci Rep"},{"key":"5229_CR66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.intimp.2018.12.001","volume":"67","author":"Z Li","year":"2019","unstructured":"Li Z, et al. Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int Immunopharmacol. 2019;67:268\u201380.","journal-title":"Int Immunopharmacol"},{"key":"5229_CR67","doi-asserted-by":"publisher","first-page":"107207","DOI":"10.1016\/j.intimp.2020.107207","volume":"90","author":"A Fathollahi","year":"2021","unstructured":"Fathollahi A, et al. Intranasal administration of small extracellular vesicles derived from mesenchymal stem cells ameliorated the experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2021;90:107207.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"5229_CR68","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/WNR.0000000000002187","volume":"36","author":"Y Ye","year":"2025","unstructured":"Ye Y, et al. Intravenous administration of mesenchymal stem cell-derived exosomes mitigates traumatic brain injury by inhibiting neutrophil extracellular trap formation via miR-26a-5p. NeuroReport. 2025;36(12):651\u201368.","journal-title":"NeuroReport"},{"key":"5229_CR69","doi-asserted-by":"publisher","first-page":"111146","DOI":"10.1016\/j.cellsig.2024.111146","volume":"119","author":"L Zhao","year":"2024","unstructured":"Zhao L, Li J. Microglial uptake of hADSCs-Exo mitigates neuroinflammation in ICH. Cell Signal. 2024;119:111146.","journal-title":"Cell Signal"},{"issue":"2","key":"5229_CR70","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.18632\/aging.202466","volume":"13","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. Human umbilical cord mesenchymal stem cell-derived exosomal miR-146a-5p reduces microglial-mediated neuroinflammation via suppression of the IRAK1\/TRAF6 signaling pathway after ischemic stroke. Aging. 2021;13(2):3060\u201379.","journal-title":"Aging"},{"issue":"6","key":"5229_CR71","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.18632\/aging.205638","volume":"16","author":"J Gu","year":"2024","unstructured":"Gu J, et al. BMSCs-derived exosomes inhibit macrophage\/microglia pyroptosis by increasing autophagy through the miR-21a-5p\/PELI1 axis in spinal cord injury. Aging. 2024;16(6):5184\u2013206.","journal-title":"Aging"},{"key":"5229_CR72","doi-asserted-by":"publisher","first-page":"110434","DOI":"10.1016\/j.abb.2025.110434","volume":"769","author":"D Li","year":"2025","unstructured":"Li D, et al. Bone marrow mesenchymal stem cells-derived exosomal miR-24-3p alleviates spinal cord injury by targeting MAPK9 to inhibit the JNK\/c-Jun\/c-Fos pathway. Arch Biochem Biophys. 2025;769:110434.","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"5229_CR73","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1007\/s12035-024-03914-1","volume":"61","author":"L Lin","year":"2024","unstructured":"Lin L, et al. MSC-Derived Extracellular Vesicles Alleviate NLRP3\/GSDMD-Mediated Neuroinflammation in Mouse Model of Sporadic Alzheimer\u2019s Disease. Mol Neurobiol. 2024;61(8):5494\u2013509.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"5229_CR74","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12974-022-02578-9","volume":"19","author":"Y Lu","year":"2022","unstructured":"Lu Y, et al. Human PMSCs-derived small extracellular vesicles alleviate neuropathic pain through miR-26a-5p\/Wnt5a in SNI mice model. J Neuroinflammation. 2022;19(1):221.","journal-title":"J Neuroinflammation"},{"key":"5229_CR75","doi-asserted-by":"crossref","unstructured":"Zampieri LX et al. Mitochondrial transfer in cancer: a comprehensive review. Int J Mol Sci. 2021;22(6):3245.","DOI":"10.3390\/ijms22063245"},{"issue":"9","key":"5229_CR76","doi-asserted-by":"publisher","first-page":"e12951","DOI":"10.1111\/tra.12951","volume":"25","author":"H Liu","year":"2024","unstructured":"Liu H, et al. Intercellular Mitochondrial Transfer: The Novel Therapeutic Mechanism for Diseases. Traffic. 2024;25(9):e12951.","journal-title":"Traffic"},{"issue":"29","key":"5229_CR77","doi-asserted-by":"publisher","first-page":"e2311571","DOI":"10.1002\/smll.202311571","volume":"20","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, et al. Ameliorating Mitochondrial Dysfunction for the Therapy of Parkinson\u2019s Disease. Small. 2024;20(29):e2311571.","journal-title":"Small"},{"key":"5229_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.phrs.2018.03.010","volume":"131","author":"V Shoshan-Barmatz","year":"2018","unstructured":"Shoshan-Barmatz V, et al. VDAC1, mitochondrial dysfunction, and Alzheimer\u2019s disease. Pharmacol Res. 2018;131:87\u2013101.","journal-title":"Pharmacol Res"},{"key":"5229_CR79","doi-asserted-by":"crossref","unstructured":"Duranti E, Villa C. Muscle involvement in amyotrophic lateral sclerosis: understanding the pathogenesis and advancing therapeutics. Biomolecules. 2023;13(11):1582 .","DOI":"10.3390\/biom13111582"},{"key":"5229_CR80","doi-asserted-by":"publisher","first-page":"1011225","DOI":"10.3389\/fnmol.2022.1011225","volume":"15","author":"S Regmi","year":"2022","unstructured":"Regmi S, et al. Mesenchymal stromal cells for the treatment of Alzheimer\u2019s disease: Strategies and limitations. Front Mol Neurosci. 2022;15:1011225.","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"5229_CR81","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.4103\/1673-5374.255978","volume":"14","author":"EE Reza-Zaldivar","year":"2019","unstructured":"Reza-Zaldivar EE, et al. Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer\u2019s disease. Neural Regen Res. 2019;14(9):1626\u201334.","journal-title":"Neural Regen Res"},{"issue":"1","key":"5229_CR82","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40478-018-0644-8","volume":"6","author":"N Boukelmoune","year":"2018","unstructured":"Boukelmoune N, et al. Mitochondrial transfer from mesenchymal stem cells to neural stem cells protects against the neurotoxic effects of cisplatin. Acta Neuropathol Commun. 2018;6(1):139.","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"5229_CR83","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4103\/1673-5374.266058","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, et al. Transfer of mitochondria from mesenchymal stem cells derived from induced pluripotent stem cells attenuates hypoxia-ischemia-induced mitochondrial dysfunction in PC12 cells. Neural Regen Res. 2020;15(3):464\u201372.","journal-title":"Neural Regen Res"},{"issue":"2","key":"5229_CR84","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3233\/JAD-190853","volume":"72","author":"K Nitzan","year":"2019","unstructured":"Nitzan K, et al. Mitochondrial Transfer Ameliorates Cognitive Deficits, Neuronal Loss, and Gliosis in Alzheimer\u2019s Disease Mice. J Alzheimers Dis. 2019;72(2):587\u2013604.","journal-title":"J Alzheimers Dis"},{"key":"5229_CR85","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fnmol.2018.00140","volume":"11","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, et al. Transplantation of Human Menstrual Blood-Derived Mesenchymal Stem Cells Alleviates Alzheimer\u2019s Disease-Like Pathology in APP\/PS1 Transgenic Mice. Front Mol Neurosci. 2018;11:140.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"5229_CR86","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13036-023-00361-9","volume":"17","author":"VV Maldonado","year":"2023","unstructured":"Maldonado VV, et al. Clinical utility of mesenchymal stem\/stromal cells in regenerative medicine and cellular therapy. J Biol Eng. 2023;17(1):44.","journal-title":"J Biol Eng"},{"issue":"4","key":"5229_CR87","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1016\/j.neurot.2024.e00355","volume":"21","author":"H Eo","year":"2024","unstructured":"Eo H, et al. Mitochondrial transplantation exhibits neuroprotective effects and improves behavioral deficits in an animal model of Parkinson\u2019s disease. Neurotherapeutics. 2024;21(4):e00355.","journal-title":"Neurotherapeutics"},{"key":"5229_CR88","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.redox.2023.102871","volume":"67","author":"S Yao","year":"2023","unstructured":"Yao S, et al. Mesenchymal stem cell attenuates spinal cord injury by inhibiting mitochondrial quality control-associated neuronal ferroptosis. Redox Biol. 2023;67:102871.","journal-title":"Redox Biol"},{"key":"5229_CR89","doi-asserted-by":"publisher","first-page":"1207748","DOI":"10.3389\/fcell.2023.1207748","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, et al. ROS-responsive exogenous functional mitochondria can rescue neural cells post-ischemic stroke. Front Cell Dev Biol. 2023;11:1207748.","journal-title":"Front Cell Dev Biol"},{"key":"5229_CR90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mvr.2019.01.001","volume":"123","author":"K Liu","year":"2019","unstructured":"Liu K, et al. Mesenchymal stem cells transfer mitochondria into cerebral microvasculature and promote recovery from ischemic stroke. Microvasc Res. 2019;123:74\u201380.","journal-title":"Microvasc Res"},{"key":"5229_CR91","doi-asserted-by":"publisher","first-page":"p130763","DOI":"10.1155\/2013\/130763","volume":"2013","author":"A Sohni","year":"2013","unstructured":"Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:p130763.","journal-title":"Stem Cells Int"},{"issue":"4","key":"5229_CR92","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000143110","volume":"35","author":"R Henschler","year":"2008","unstructured":"Henschler R, Deak E, Seifried E. Homing of Mesenchymal Stem Cells. Transfus Med Hemother. 2008;35(4):306\u201312.","journal-title":"Transfus Med Hemother"},{"key":"5229_CR93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. iScience. 2019;15:421\u201338.","journal-title":"iScience"},{"issue":"6","key":"5229_CR94","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00395-005-0552-5","volume":"100","author":"B Dawn","year":"2005","unstructured":"Dawn B, Bolli R. Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol. 2005;100(6):494\u2013503.","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"5229_CR95","first-page":"168","volume":"20","author":"M Fesharaki","year":"2018","unstructured":"Fesharaki M, et al. Differentiation of Human Scalp Adipose-Derived Mesenchymal Stem Cells into Mature Neural Cells on Electrospun Nanofibrous Scaffolds for Nerve Tissue Engineering Applications. Cell J. 2018;20(2):168\u201376.","journal-title":"Cell J"},{"key":"5229_CR96","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biomaterials.2018.01.015","volume":"160","author":"YH Ma","year":"2018","unstructured":"Ma YH, et al. Perineurium-like sheath derived from long-term surviving mesenchymal stem cells confers nerve protection to the injured spinal cord. Biomaterials. 2018;160:37\u201355.","journal-title":"Biomaterials"},{"key":"5229_CR97","doi-asserted-by":"publisher","first-page":"102482","DOI":"10.1016\/j.amsu.2021.102482","volume":"67","author":"T Sumarwoto","year":"2021","unstructured":"Sumarwoto T, et al. Role of adipose mesenchymal stem cells and secretome in peripheral nerve regeneration. Annals Med Surg. 2021;67:102482.","journal-title":"Annals Med Surg"},{"key":"5229_CR98","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3389\/fimmu.2018.02837","volume":"9","author":"JR Ferreira","year":"2018","unstructured":"Ferreira JR, et al. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning. Front Immunol. 2018;9:2837.","journal-title":"Front Immunol"},{"key":"5229_CR99","doi-asserted-by":"crossref","unstructured":"Cofano F et al. Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int J Mol Sci. 2019;20(11):2698.","DOI":"10.3390\/ijms20112698"},{"key":"5229_CR100","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.npep.2020.102095","volume":"84","author":"S Barati","year":"2020","unstructured":"Barati S, Tahmasebi F, Faghihi F. Effects of mesenchymal stem cells transplantation on multiple sclerosis patients. Neuropeptides. 2020;84:102095.","journal-title":"Neuropeptides"},{"issue":"1","key":"5229_CR101","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s13287-021-02563-8","volume":"12","author":"C Brown","year":"2021","unstructured":"Brown C, et al. Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Stem Cell Res Ther. 2021;12(1):499.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13287-015-0272-1","volume":"7","author":"MM Bakhuraysah","year":"2016","unstructured":"Bakhuraysah MM, Siatskas C, Petratos S. Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? Stem Cell Res Ther. 2016;7(1):12.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR103","doi-asserted-by":"publisher","first-page":"963689724123304","DOI":"10.1177\/09636897241233045","volume":"33","author":"F Jamali","year":"2024","unstructured":"Jamali F, et al. Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I\/II Dose-Finding Clinical Study. Cell Transpl. 2024;33:9636897241233045.","journal-title":"Cell Transpl"},{"key":"5229_CR104","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","volume":"29","author":"VK Harris","year":"2018","unstructured":"Harris VK, et al. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018;29:23\u201330.","journal-title":"EBioMedicine"},{"issue":"1","key":"5229_CR105","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13287-024-03765-6","volume":"15","author":"VK Harris","year":"2024","unstructured":"Harris VK, et al. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Res Ther. 2024;15(1):151.","journal-title":"Stem Cell Res Ther"},{"issue":"Supplement1","key":"5229_CR106","doi-asserted-by":"publisher","first-page":"p10308","DOI":"10.4049\/jimmunol.208.Supp.103.08","volume":"208","author":"AW Boyden","year":"2022","unstructured":"Boyden AW, et al. B cell-mediated antigen presentation is required to induce functional pathogenicity of CD4 T cells in a proteolipid protein mouse model of multiple sclerosis. J Immunol. 2022;208(Supplement1):p10308\u201310308.","journal-title":"J Immunol"},{"issue":"2","key":"5229_CR107","first-page":"65","volume":"27","author":"YM Almatrafi","year":"2022","unstructured":"Almatrafi YM, et al. Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah. Saudi Arabia Neurosciences (Riyadh). 2022;27(2):65\u201370.","journal-title":"Saudi Arabia Neurosciences (Riyadh)"},{"key":"5229_CR108","doi-asserted-by":"crossref","unstructured":"Fan L et al. Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci. 2016;17(5):650.","DOI":"10.3390\/ijms17050650"},{"issue":"3","key":"5229_CR109","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/stem.1555","volume":"32","author":"S Yoshioka","year":"2014","unstructured":"Yoshioka S, et al. CCAAT\/enhancer-binding protein \u03b2 expressed by bone marrow mesenchymal stromal cells regulates early B-cell lymphopoiesis. Stem Cells. 2014;32(3):730\u201340.","journal-title":"Stem Cells"},{"issue":"1","key":"5229_CR110","doi-asserted-by":"publisher","first-page":"16005","DOI":"10.1038\/s41598-025-00590-6","volume":"15","author":"A Shokati","year":"2025","unstructured":"Shokati A, et al. Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial. Sci Rep. 2025;15(1):16005.","journal-title":"Sci Rep"},{"issue":"12","key":"5229_CR111","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1093\/brain\/awaa333","volume":"143","author":"P Petrou","year":"2020","unstructured":"Petrou P, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12):3574\u201388.","journal-title":"Brain"},{"issue":"22","key":"5229_CR112","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230\u20137.","journal-title":"Neurology"},{"issue":"1","key":"5229_CR113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/stcltm\/szab017","volume":"11","author":"P Petrou","year":"2022","unstructured":"Petrou P, et al. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis. Stem Cells Transl Med. 2022;11(1):55\u20138.","journal-title":"Stem Cells Transl Med"},{"key":"5229_CR114","doi-asserted-by":"publisher","first-page":"578613","DOI":"10.1016\/j.jneuroim.2025.578613","volume":"403","author":"P Petrou","year":"2025","unstructured":"Petrou P, et al. Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01). J Neuroimmunol. 2025;403:578613.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"5229_CR115","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/13524585221122156","volume":"29","author":"JA Cohen","year":"2023","unstructured":"Cohen JA, et al. Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Mult Scler. 2023;29(1):92\u2013106.","journal-title":"Mult Scler"},{"key":"5229_CR116","doi-asserted-by":"publisher","first-page":"103779","DOI":"10.1016\/j.msard.2022.103779","volume":"61","author":"JA Berard","year":"2022","unstructured":"Berard JA, et al. Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. Mult Scler Relat Disord. 2022;61:103779.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"5229_CR117","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","volume":"20","author":"A Uccelli","year":"2021","unstructured":"Uccelli A, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol. 2021;20(11):917\u201329.","journal-title":"Lancet Neurol"},{"issue":"9769","key":"5229_CR118","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942\u201355.","journal-title":"Lancet"},{"issue":"2","key":"5229_CR119","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/scrt421","volume":"5","author":"CM Lewis","year":"2014","unstructured":"Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther. 2014;5(2):32.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5229_CR120","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/1533317507301613","volume":"22","author":"D Irwin","year":"2007","unstructured":"Irwin D, Lippa CF, Swearer JM. Cognition and amyotrophic lateral sclerosis (ALS). Am J Alzheimers Dis Other Demen. 2007;22(4):300\u201312.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"10","key":"5229_CR121","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918\u201329.","journal-title":"Eur J Neurol"},{"issue":"1","key":"5229_CR122","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13287-024-03748-7","volume":"15","author":"LE Mesa Bedoya","year":"2024","unstructured":"Mesa Bedoya LE, et al. The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials. Stem Cell Res Ther. 2024;15(1):146.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"5229_CR123","doi-asserted-by":"publisher","first-page":"e014985","DOI":"10.1136\/bmjopen-2016-014985","volume":"7","author":"M Galvin","year":"2017","unstructured":"Galvin M, et al. From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohort-a thematic analysis. BMJ Open. 2017;7(3):e014985.","journal-title":"BMJ Open"},{"key":"5229_CR124","unstructured":"Richards D, Morren JA, Pioro EP, Araki T. Exon Publications Copyright: The Authors.: Brisbane (AU). 2021."},{"key":"5229_CR125","first-page":"61","volume":"7","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61\u201370.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"9","key":"5229_CR126","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N Engl J Med. 1994;330(9):585\u201391.","journal-title":"N Engl J Med"},{"issue":"9013","key":"5229_CR127","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet. 1996;347(9013):1425\u201331.","journal-title":"Lancet"},{"key":"5229_CR128","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.reth.2021.07.006","volume":"18","author":"J Tavakol-Afshari","year":"2021","unstructured":"Tavakol-Afshari J, et al. Safety and efficacy of bone marrow derived-mesenchymal stem cells transplantation in patients with amyotrophic lateral sclerosis. Regen Ther. 2021;18:268\u201374.","journal-title":"Regen Ther"},{"issue":"5","key":"5229_CR129","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s12015-020-10016-7","volume":"16","author":"M Barczewska","year":"2020","unstructured":"Barczewska M, et al. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem Cell Rev Rep. 2020;16(5):922\u201332.","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"5229_CR130","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3727\/096368916X693716","volume":"26","author":"E Sykov\u00e1","year":"2017","unstructured":"Sykov\u00e1 E, et al. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I\/IIa Clinical Trial. Cell Transpl. 2017;26(4):647\u201358.","journal-title":"Cell Transpl"},{"issue":"21","key":"5229_CR131","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000003359","volume":"87","author":"NP Staff","year":"2016","unstructured":"Staff NP, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016;87(21):2230\u20134.","journal-title":"Neurology"},{"issue":"1","key":"5229_CR132","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17582024.2025.2553499","volume":"16","author":"S Karimi","year":"2026","unstructured":"Karimi S, et al. Intravenous vs intrathecal transplantation of allogeneic GMP\/GCP compliant Wharton\u2019s jelly mesenchymal stromal cells in ALS patients: a phase I study. Neurodegener Dis Manag. 2026;16(1):33\u201341.","journal-title":"Neurodegener Dis Manag"},{"key":"5229_CR133","doi-asserted-by":"publisher","first-page":"e927484","DOI":"10.12659\/MSM.927484","volume":"26","author":"T Siwek","year":"2020","unstructured":"Siwek T, et al. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis. Med Sci Monit. 2020;26:e927484.","journal-title":"Med Sci Monit"},{"issue":"1","key":"5229_CR134","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1038\/s41598-017-09097-1","volume":"7","author":"Y Hu","year":"2017","unstructured":"Hu Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7(1):9094.","journal-title":"Sci Rep"},{"issue":"10","key":"5229_CR135","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41593-019-0486-0","volume":"22","author":"AU Joshi","year":"2019","unstructured":"Joshi AU, et al. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci. 2019;22(10):1635\u201348.","journal-title":"Nat Neurosci"},{"key":"5229_CR136","doi-asserted-by":"crossref","unstructured":"Alkhazaali-Ali Z et al. Evaluation of the safety and efficacy of repeated mesenchymal stem cell transplantations in ALS patients by investigating patients\u2019 specific immunological and biochemical biomarkers. Diseases. 2024;12(5):9 .","DOI":"10.3390\/diseases12050099"},{"key":"5229_CR137","doi-asserted-by":"publisher","first-page":"110760","DOI":"10.1016\/j.brainresbull.2023.110760","volume":"202","author":"J Tang","year":"2023","unstructured":"Tang J, et al. Umbilical cord mesenchymal stem cell-conditioned medium inhibits microglial activation to ameliorate neuroinflammation in amyotrophic lateral sclerosis mice and cell models. Brain Res Bull. 2023;202:110760.","journal-title":"Brain Res Bull"},{"issue":"24","key":"5229_CR138","doi-asserted-by":"publisher","first-page":"e2294","DOI":"10.1212\/WNL.0000000000008620","volume":"93","author":"JD Berry","year":"2019","unstructured":"Berry JD, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. 2019;93(24):e2294\u2013305.","journal-title":"Neurology"},{"issue":"1","key":"5229_CR139","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13287-024-03820-2","volume":"15","author":"ALG Reis","year":"2024","unstructured":"Reis ALG, et al. Proteomic analysis of cerebrospinal fluid of amyotrophic lateral sclerosis patients in the presence of autologous bone marrow derived mesenchymal stem cells. Stem Cell Res Ther. 2024;15(1):301.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR140","doi-asserted-by":"crossref","unstructured":"Spinal Cord Injury (SCI). 2016 Facts and figures at a glance. J Spinal Cord Med. 2016;39(4):493\u20134.","DOI":"10.1080\/10790268.2016.1210925"},{"key":"5229_CR141","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fneur.2019.00282","volume":"10","author":"A Alizadeh","year":"2019","unstructured":"Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. Front Neurol. 2019;10:282.","journal-title":"Front Neurol"},{"key":"5229_CR142","doi-asserted-by":"publisher","first-page":"701927","DOI":"10.3389\/fneur.2021.701927","volume":"12","author":"L M\u00fcller-Jensen","year":"2021","unstructured":"M\u00fcller-Jensen L, et al. Clinical Presentation and Causes of Non-traumatic Spinal Cord Injury: An Observational Study in Emergency Patients. Front Neurol. 2021;12:701927.","journal-title":"Front Neurol"},{"issue":"15","key":"5229_CR143","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1523\/JNEUROSCI.22-15-06670.2002","volume":"22","author":"T Takami","year":"2002","unstructured":"Takami T, et al. Schwann cell but not olfactory ensheathing glia transplants improve hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord. J Neurosci. 2002;22(15):6670\u201381.","journal-title":"J Neurosci"},{"issue":"39","key":"5229_CR144","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1523\/JNEUROSCI.1998-04.2004","volume":"24","author":"M Sasaki","year":"2004","unstructured":"Sasaki M, et al. Identified olfactory ensheathing cells transplanted into the transected dorsal funiculus bridge the lesion and form myelin. J Neurosci. 2004;24(39):8485\u201393.","journal-title":"J Neurosci"},{"issue":"1","key":"5229_CR145","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1006\/exnr.2000.7539","volume":"167","author":"Y Akiyama","year":"2001","unstructured":"Akiyama Y, et al. Transplantation of clonal neural precursor cells derived from adult human brain establishes functional peripheral myelin in the rat spinal cord. Exp Neurol. 2001;167(1):27\u201339.","journal-title":"Exp Neurol"},{"key":"5229_CR146","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.neuroscience.2016.08.037","volume":"335","author":"T Morita","year":"2016","unstructured":"Morita T, et al. Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience. 2016;335:221\u201331.","journal-title":"Neuroscience"},{"issue":"3","key":"5229_CR147","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/neu.2018.5793","volume":"36","author":"T Oshigiri","year":"2019","unstructured":"Oshigiri T, et al. Intravenous Infusion of Mesenchymal Stem Cells Alters Motor Cortex Gene Expression in a Rat Model of Acute Spinal Cord Injury. J Neurotrauma. 2019;36(3):411\u201320.","journal-title":"J Neurotrauma"},{"issue":"1","key":"5229_CR148","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13287-024-03770-9","volume":"15","author":"J-W Kim","year":"2024","unstructured":"Kim J-W, et al. Combination of induced pluripotent stem cell-derived motor neuron progenitor cells with irradiated brain-derived neurotrophic factor over-expressing engineered mesenchymal stem cells enhanced restoration of axonal regeneration in a chronic spinal cord injury rat model. Stem Cell Res Ther. 2024;15(1):173.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR149","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13287-024-03714-3","volume":"15","author":"J-W Kim","year":"2024","unstructured":"Kim J-W, et al. Stepwise combined cell transplantation using mesenchymal stem cells and induced pluripotent stem cell-derived motor neuron progenitor cells in spinal cord injury. Stem Cell Res Ther. 2024;15(1):114.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR150","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13287-020-01724-5","volume":"11","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, et al. Adipose mesenchymal stem cell transplantation alleviates spinal cord injury-induced neuroinflammation partly by suppressing the Jagged1\/Notch pathway. Stem Cell Res Ther. 2020;11(1):212.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5229_CR151","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13287-016-0295-2","volume":"7","author":"M Yousefifard","year":"2016","unstructured":"Yousefifard M, et al. Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model. Stem Cell Res Ther. 2016;7(1):36.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"5229_CR152","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/scrt516","volume":"5","author":"MV Mendon\u00e7a","year":"2014","unstructured":"Mendon\u00e7a MV, et al. Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury. Stem Cell Res Ther. 2014;5(6):126.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"5229_CR153","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2020.08.008","volume":"23","author":"S Albu","year":"2021","unstructured":"Albu S, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021;23(2):146\u201356.","journal-title":"Cytotherapy"},{"key":"5229_CR154","doi-asserted-by":"publisher","first-page":"106565","DOI":"10.1016\/j.clineuro.2021.106565","volume":"203","author":"O Honmou","year":"2021","unstructured":"Honmou O, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021;203:106565.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"5229_CR155","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13287-021-02305-w","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, et al. CD157 in bone marrow mesenchymal stem cells mediates mitochondrial production and transfer to improve neuronal apoptosis and functional recovery after spinal cord injury. Stem Cell Res Ther. 2021;12(1):289.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR156","doi-asserted-by":"publisher","first-page":"123402","DOI":"10.1016\/j.wneu.2024.10.131","volume":"194","author":"M Akhlaghpasand","year":"2025","unstructured":"Akhlaghpasand M, et al. Improvement of Neurogenic Bladder Dysfunction Following Combined Cell Therapy with Mesenchymal Stem Cell and Schwann Cell in Spinal Cord Injury: A Randomized, Open-Label, Phase II Clinical Trial. World Neurosurg. 2025;194:123402.","journal-title":"World Neurosurg"},{"issue":"1","key":"5229_CR157","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41393-021-00687-5","volume":"60","author":"H Zamani","year":"2022","unstructured":"Zamani H, et al. Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial. Spinal Cord. 2022;60(1):63\u201370.","journal-title":"Spinal Cord"},{"issue":"8","key":"5229_CR158","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jcyt.2024.03.480","volume":"26","author":"A Awidi","year":"2024","unstructured":"Awidi A, et al. Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord origins in patients with chronic spinal cord injuries: a phase I\/II study. Cytotherapy. 2024;26(8):825\u201331.","journal-title":"Cytotherapy"},{"issue":"5","key":"5229_CR159","doi-asserted-by":"publisher","first-page":"101675","DOI":"10.4252\/wjsc.v17.i5.101675","volume":"17","author":"N Kaplan","year":"2025","unstructured":"Kaplan N, et al. Multiroute administration of Wharton\u2019s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study. World J Stem Cells. 2025;17(5):101675.","journal-title":"World J Stem Cells"},{"issue":"1","key":"5229_CR160","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/s41467-024-46259-y","volume":"15","author":"M Bydon","year":"2024","unstructured":"Bydon M, et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. Nat Commun. 2024;15(1):2201.","journal-title":"Nat Commun"},{"issue":"9","key":"5229_CR161","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41582-018-0043-6","volume":"14","author":"SJ Korzeniewski","year":"2018","unstructured":"Korzeniewski SJ, et al. The complex aetiology of cerebral palsy. Nat Rev Neurol. 2018;14(9):528\u201343.","journal-title":"Nat Rev Neurol"},{"issue":"9924","key":"5229_CR162","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(13)61835-8","volume":"383","author":"A Colver","year":"2014","unstructured":"Colver A, Fairhurst C, Pharoah PO. Cerebral palsy. Lancet. 2014;383(9924):1240\u20139.","journal-title":"Lancet"},{"issue":"1","key":"5229_CR163","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/dmcn.15640","volume":"66","author":"K Ostojic","year":"2024","unstructured":"Ostojic K, et al. Social determinants of health for children with cerebral palsy and their families. Dev Med Child Neurol. 2024;66(1):32\u201340.","journal-title":"Dev Med Child Neurol"},{"key":"5229_CR164","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/CLEP.S205839","volume":"11","author":"DG Whitney","year":"2019","unstructured":"Whitney DG, et al. Prevalence of high-burden medical conditions and health care resource utilization and costs among adults with cerebral palsy. Clin Epidemiol. 2019;11:469\u201381.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"5229_CR165","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/0963689717729379","volume":"27","author":"L Huang","year":"2018","unstructured":"Huang L, Randomized A, et al. Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy. Cell Transpl. 2018;27(2):325\u201334.","journal-title":"Cell Transpl"},{"issue":"1","key":"5229_CR166","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13287-019-1545-x","volume":"11","author":"J Gu","year":"2020","unstructured":"Gu J, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11(1):43.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"5229_CR167","first-page":"1041","volume":"32","author":"I Dori","year":"2017","unstructured":"Dori I, et al. Seven days post-injury fate and effects of genetically labelled adipose-derived mesenchymal cells on a rat traumatic brain injury experimental model. Histol Histopathol. 2017;32(10):1041\u201355.","journal-title":"Histol Histopathol"},{"issue":"4","key":"5229_CR168","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/scd.2016.0108","volume":"26","author":"M Mueller","year":"2017","unstructured":"Mueller M, et al. Wharton\u2019s Jelly Mesenchymal Stem Cells Protect the Immature Brain in Rats and Modulate Cell Fate. Stem Cells Dev. 2017;26(4):239\u201348.","journal-title":"Stem Cells Dev"},{"issue":"11","key":"5229_CR169","doi-asserted-by":"publisher","first-page":"e1118","DOI":"10.1097\/CCM.0000000000001864","volume":"44","author":"F Pischiutta","year":"2016","unstructured":"Pischiutta F, et al. Protection of Brain Injury by Amniotic Mesenchymal Stromal Cell-Secreted Metabolites. Crit Care Med. 2016;44(11):e1118\u201331.","journal-title":"Crit Care Med"},{"key":"5229_CR170","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.12659\/MSM.900512","volume":"22","author":"J Xie","year":"2016","unstructured":"Xie J, et al. Intracerebral and Intravenous Transplantation Represents a Favorable Approach for Application of Human Umbilical Cord Mesenchymal Stromal Cells in Intracerebral Hemorrhage Rats. Med Sci Monit. 2016;22:3552\u201361.","journal-title":"Med Sci Monit"},{"issue":"12","key":"5229_CR171","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/dmcn.15325","volume":"64","author":"JM Sun","year":"2022","unstructured":"Sun JM, et al. Motor function and safety after allogeneic cord blood and cord tissue-derived mesenchymal stromal cells in cerebral palsy: An open-label, randomized trial. Dev Med Child Neurol. 2022;64(12):1477\u201386.","journal-title":"Dev Med Child Neurol"},{"issue":"9","key":"5229_CR172","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.12998\/wjcc.v12.i9.1585","volume":"12","author":"O Boyal\u0131","year":"2024","unstructured":"Boyal\u0131 O, et al. Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy. World J Clin Cases. 2024;12(9):1585\u201396.","journal-title":"World J Clin Cases"},{"issue":"1","key":"5229_CR173","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pneurobio.2006.11.009","volume":"81","author":"N Singh","year":"2007","unstructured":"Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson\u2019s disease. Prog Neurobiol. 2007;81(1):29\u201344.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"5229_CR174","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13287-023-03280-0","volume":"14","author":"Y Zhuo","year":"2023","unstructured":"Zhuo Y, et al. Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson\u2019s disease. Stem Cell Res Ther. 2023;14(1):80.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"5229_CR175","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, et al. Global, regional, and national burden of neurological disorders,1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459\u201380.","journal-title":"Lancet Neurol"},{"issue":"2","key":"5229_CR176","first-page":"183","volume":"32","author":"O Hornykiewicz","year":"1973","unstructured":"Hornykiewicz O. Parkinson\u2019s disease: from brain homogenate to treatment. Fed Proc. 1973;32(2):183\u201390.","journal-title":"Fed Proc"},{"key":"5229_CR177","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.","journal-title":"Transl Neurodegener"},{"key":"5229_CR178","doi-asserted-by":"crossref","unstructured":"More SV, et al. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson\u2019s disease. Mediators Inflamm. 2013;2013:952375.","DOI":"10.1155\/2013\/952375"},{"key":"5229_CR179","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neuroscience.2015.03.011","volume":"302","author":"A Roy","year":"2015","unstructured":"Roy A, et al. Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey. Neuroscience. 2015;302:36\u201346.","journal-title":"Neuroscience"},{"issue":"7660","key":"5229_CR180","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer D, et al. T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature. 2017;546(7660):656\u201361.","journal-title":"Nature"},{"issue":"6","key":"5229_CR181","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer W, Przedborski S. Parkinson\u2019s disease: mechanisms and models. Neuron. 2003;39(6):889\u2013909.","journal-title":"Neuron"},{"issue":"4","key":"5229_CR182","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"5229_CR183","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease. Arch Neurol. 2000;57(10):1461\u20133.","journal-title":"Arch Neurol"},{"issue":"5","key":"5229_CR184","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002512-199710050-00005","volume":"10","author":"BK Young","year":"1997","unstructured":"Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging. 1997;10(5):367\u201383.","journal-title":"Drugs Aging"},{"issue":"1","key":"5229_CR185","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/aian.aian_474_21","volume":"25","author":"KB Bhattacharyya","year":"2022","unstructured":"Bhattacharyya KB. The Story of Levodopa: A Long and Arduous Journey. Ann Indian Acad Neurol. 2022;25(1):124\u201330.","journal-title":"Ann Indian Acad Neurol"},{"issue":"5","key":"5229_CR186","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00401-016-1605-6","volume":"132","author":"HJ Park","year":"2016","unstructured":"Park HJ, et al. Mesenchymal stem cells enhance \u03b1-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder. Acta Neuropathol. 2016;132(5):685\u2013701.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"5229_CR187","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.celrep.2015.12.075","volume":"14","author":"SH Oh","year":"2016","unstructured":"Oh SH, et al. Mesenchymal Stem Cells Inhibit Transmission of \u03b1-Synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model. Cell Rep. 2016;14(4):835\u201349.","journal-title":"Cell Rep"},{"issue":"3","key":"5229_CR188","doi-asserted-by":"publisher","first-page":"949","DOI":"10.5966\/sctm.2016-0111","volume":"6","author":"SH Oh","year":"2017","unstructured":"Oh SH, et al. The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular \u03b1-Synuclein Aggregates in Parkinsonian Models. Stem Cells Transl Med. 2017;6(3):949\u201361.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"5229_CR189","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-016-0880-2","volume":"14","author":"M Canesi","year":"2016","unstructured":"Canesi M, et al. Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016;14(1):127.","journal-title":"J Transl Med"},{"issue":"1","key":"5229_CR190","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13287-025-04577-y","volume":"16","author":"JD Martinez-Lemus","year":"2025","unstructured":"Martinez-Lemus JD, et al. Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson\u2019s disease clinical trial. Stem Cell Res Ther. 2025;16(1):493.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"5229_CR191","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trsl.2009.07.006","volume":"155","author":"NK Venkataramana","year":"2010","unstructured":"Venkataramana NK, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson\u2019s disease. Transl Res. 2010;155(2):62\u201370.","journal-title":"Transl Res"},{"issue":"9","key":"5229_CR192","doi-asserted-by":"publisher","first-page":"140447","DOI":"10.1016\/j.bbapap.2020.140447","volume":"1868","author":"S Beltr\u00e1n-Castillo","year":"2020","unstructured":"Beltr\u00e1n-Castillo S, et al. TGF\u03b21-Smad3 signaling mediates the formation of a stable serine racemase dimer in microglia. Biochim Biophys Acta Proteins Proteom. 2020;1868(9):140447.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"5229_CR193","doi-asserted-by":"publisher","first-page":"109249","DOI":"10.1016\/j.cbi.2020.109249","volume":"331","author":"HY Chen","year":"2020","unstructured":"Chen HY, et al. TGF-\u03b21 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1\/Nrf2 pathway. Chem Biol Interact. 2020;331:109249.","journal-title":"Chem Biol Interact"},{"issue":"4","key":"5229_CR194","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1111\/jcmm.14147","volume":"23","author":"X Xue","year":"2019","unstructured":"Xue X, et al. Aquaporin-4 deficiency reduces TGF-\u03b21 in mouse midbrains and exacerbates pathology in experimental Parkinson\u2019s disease. J Cell Mol Med. 2019;23(4):2568\u201382.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"5229_CR195","first-page":"48","volume":"11","author":"Y Zhuo","year":"2024","unstructured":"Zhuo Y, et al. TGF-\u03b21 mediates hypoxia-preconditioned olfactory mucosa mesenchymal stem cells improved neural functional recovery in Parkinson\u2019s disease models and patients. Mil Med Res. 2024;11(1):48.","journal-title":"Mil Med Res"},{"issue":"1","key":"5229_CR196","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1706442","volume":"378","author":"RG Nogueira","year":"2018","unstructured":"Nogueira RG, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"5229_CR197","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12017-019-08533-x","volume":"21","author":"S Pianta","year":"2019","unstructured":"Pianta S, et al. A Short Bout of Exercise Prior to Stroke Improves Functional Outcomes by Enhancing Angiogenesis. Neuromolecular Med. 2019;21(4):517\u201328.","journal-title":"Neuromolecular Med"},{"issue":"1","key":"5229_CR198","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2396987319832140","volume":"4","author":"G Turc","year":"2019","unstructured":"Turc G, et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J. 2019;4(1):6\u201312.","journal-title":"Eur Stroke J"},{"issue":"1","key":"5229_CR199","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13287-022-02876-2","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, et al. Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke. Stem Cell Res Ther. 2022;13(1):195.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"5229_CR200","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12975-018-0634-y","volume":"10","author":"L Deng","year":"2019","unstructured":"Deng L, et al. Intrathecal Injection of Allogenic Bone Marrow-Derived Mesenchymal Stromal Cells in Treatment of Patients with Severe Ischemic Stroke: Study Protocol for a Randomized Controlled Observer-Blinded Trial. Transl Stroke Res. 2019;10(2):170\u20137.","journal-title":"Transl Stroke Res"},{"issue":"5","key":"5229_CR201","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12975-020-00787-z","volume":"11","author":"A Jaillard","year":"2020","unstructured":"Jaillard A, et al. Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial. Transl Stroke Res. 2020;11(5):910\u201323.","journal-title":"Transl Stroke Res"},{"key":"5229_CR202","doi-asserted-by":"publisher","first-page":"963689722108386","DOI":"10.1177\/09636897221083863","volume":"31","author":"E de Celis-Ruiz","year":"2022","unstructured":"de Celis-Ruiz E, et al. Final Results of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial. Cell Transpl. 2022;31:9636897221083863.","journal-title":"Cell Transpl"},{"issue":"1","key":"5229_CR203","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/STROKEAHA.121.034505","volume":"53","author":"J Lee","year":"2022","unstructured":"Lee J, et al. Efficacy of Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic Stroke: A Neuroimaging Study. Stroke. 2022;53(1):20\u20138.","journal-title":"Stroke"},{"key":"5229_CR204","first-page":"101486","volume":"34","author":"JH Yea","year":"2023","unstructured":"Yea JH, Kim Y, Jo CH. Comparison of mesenchymal stem cells from bone marrow, umbilical cord blood, and umbilical cord tissue in regeneration of a full-thickness tendon defect in vitro and in vivo. Biochem Biophys Rep. 2023;34:101486.","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"5229_CR205","doi-asserted-by":"publisher","first-page":"576","DOI":"10.7150\/ijms.124255","volume":"23","author":"L Chan","year":"2026","unstructured":"Chan L, Phase A, Open-Label I, et al. Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous UMC119-06 in Patients with Acute Ischemic Stroke. Int J Med Sci. 2026;23(2):576\u201384.","journal-title":"Int J Med Sci"},{"key":"5229_CR206","doi-asserted-by":"crossref","unstructured":"Nguyen LT et al. Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. Stem Cells Transl Med. 2025;14(12):szaf063.","DOI":"10.1093\/stcltm\/szaf063"},{"key":"5229_CR207","doi-asserted-by":"publisher","first-page":"811852","DOI":"10.3389\/fncel.2021.811852","volume":"15","author":"J Hu","year":"2021","unstructured":"Hu J, Wang X. Alzheimer\u2019s Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy - Bridging the Missing Link. Front Cell Neurosci. 2021;15:811852.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"5229_CR208","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13287-017-0567-5","volume":"8","author":"T Duncan","year":"2017","unstructured":"Duncan T, Valenzuela M. Alzheimer\u2019s disease, dementia, and stem cell therapy. Stem Cell Res Ther. 2017;8(1):111.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR209","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev.ne.17.030194.002421","volume":"17","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci. 1994;17:489\u2013517.","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"5229_CR210","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13287-022-02765-8","volume":"13","author":"C Qin","year":"2022","unstructured":"Qin C, et al. The functional mechanism of bone marrow-derived mesenchymal stem cells in the treatment of animal models with Alzheimer\u2019s disease: crosstalk between autophagy and apoptosis. Stem Cell Res Ther. 2022;13(1):90.","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"5229_CR211","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","volume":"91","author":"AC Alonso","year":"1994","unstructured":"Alonso AC, et al. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91(12):5562\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5229_CR212","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13287-024-03737-w","volume":"15","author":"Z Cao","year":"2024","unstructured":"Cao Z, et al. Promoting Alzheimer\u2019s disease research and therapy with stem cell technology. Stem Cell Res Ther. 2024;15(1):136.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"5229_CR213","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"K Iqbal","year":"2010","unstructured":"Iqbal K, et al. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7(8):656\u201364.","journal-title":"Curr Alzheimer Res"},{"issue":"8504","key":"5229_CR214","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0140-6736(86)92134-3","volume":"2","author":"K Iqbal","year":"1986","unstructured":"Iqbal K, et al. Defective brain microtubule assembly in Alzheimer\u2019s disease. Lancet. 1986;2(8504):421\u20136.","journal-title":"Lancet"},{"issue":"1","key":"5229_CR215","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-021-00897-2","volume":"13","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, et al. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021;13(1):154.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"5229_CR216","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12265-011-9257-3","volume":"4","author":"T Tallone","year":"2011","unstructured":"Tallone T, et al. Adult human adipose tissue contains several types of multipotent cells. J Cardiovasc Transl Res. 2011;4(2):200\u201310.","journal-title":"J Cardiovasc Transl Res"},{"key":"5229_CR217","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-9012-2_8","volume":"1922","author":"M Ducret","year":"2019","unstructured":"Ducret M, et al. Phenotypic Identification of Dental Pulp Mesenchymal Stem\/Stromal Cells Subpopulations with Multiparametric Flow Cytometry. Methods Mol Biol. 2019;1922:77\u201390.","journal-title":"Methods Mol Biol"},{"issue":"29","key":"5229_CR218","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1016\/j.biomaterials.2013.05.025","volume":"34","author":"H Yang","year":"2013","unstructured":"Yang H, et al. Comparison of mesenchymal stem cells derived from gingival tissue and periodontal ligament in different incubation conditions. Biomaterials. 2013;34(29):7033\u201347.","journal-title":"Biomaterials"},{"issue":"29","key":"5229_CR219","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1016\/j.biomaterials.2005.02.022","volume":"26","author":"YS Choi","year":"2005","unstructured":"Choi YS, Park SN, Suh H. Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres. Biomaterials. 2005;26(29):5855\u201363.","journal-title":"Biomaterials"},{"issue":"1","key":"5229_CR220","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13287-024-03868-0","volume":"15","author":"M Akhlaghpasand","year":"2024","unstructured":"Akhlaghpasand M, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Stem Cell Res Ther. 2024;15(1):264.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"5229_CR221","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/scd.2008.0253","volume":"18","author":"UM Fischer","year":"2009","unstructured":"Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683\u201392.","journal-title":"Stem Cells Dev"},{"issue":"12","key":"5229_CR222","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00259-014-2858-8","volume":"41","author":"C Lang","year":"2014","unstructured":"Lang C, et al. In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model. Eur J Nucl Med Mol Imaging. 2014;41(12):2325\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"5229_CR223","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/01.CIR.0000163546.27639.AA","volume":"111","author":"M Hofmann","year":"2005","unstructured":"Hofmann M, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111(17):2198\u2013202.","journal-title":"Circulation"},{"issue":"4","key":"5229_CR224","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jtcvs.2007.07.071","volume":"135","author":"X Hu","year":"2008","unstructured":"Hu X, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg. 2008;135(4):799\u2013808.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5229_CR225","doi-asserted-by":"crossref","unstructured":"Levy O et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.","DOI":"10.1126\/sciadv.aba6884"},{"issue":"6","key":"5229_CR226","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1442-200X.2007.02491.x","volume":"49","author":"T Sasaki","year":"2007","unstructured":"Sasaki T, et al. Stromal cell-derived factor-1alpha improves infarcted heart function through angiogenesis in mice. Pediatr Int. 2007;49(6):966\u201371.","journal-title":"Pediatr Int"},{"key":"5229_CR227","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.brainres.2007.11.068","volume":"1195","author":"Y Wang","year":"2008","unstructured":"Wang Y, Deng Y, Zhou G-Q. SDF-1\u03b1\/CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain Res. 2008;1195:104\u201312.","journal-title":"Brain Res"},{"issue":"7","key":"5229_CR228","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/stem.1118","volume":"30","author":"L von Bahr","year":"2012","unstructured":"von Bahr L, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575\u20138.","journal-title":"Stem Cells"},{"issue":"3","key":"5229_CR229","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252\u201360.","journal-title":"Nat Biotechnol"},{"issue":"6, Supplement","key":"5229_CR230","doi-asserted-by":"publisher","first-page":"pS46","DOI":"10.1016\/j.jcyt.2024.03.078","volume":"26","author":"M Sielski","year":"2024","unstructured":"Sielski M, et al. AGING OF MESENCHYMAL STEM CELLS IN VITRO: IMPLICATIONS IN PHENOTYPE AND DIFFERENTIATION CAPACITY. Cytotherapy. 2024;26(6, Supplement):pS46.","journal-title":"Cytotherapy"},{"issue":"4","key":"5229_CR231","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/14653249.2011.640669","volume":"14","author":"A Schellenberg","year":"2012","unstructured":"Schellenberg A, et al. Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy. 2012;14(4):401\u201311.","journal-title":"Cytotherapy"},{"issue":"7","key":"5229_CR232","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/1574888X14666190318111614","volume":"14","author":"H Rajabi","year":"2019","unstructured":"Rajabi H, et al. Current Status of Used Protocols for Mesenchymal Stem Cell Differentiation: A Focus on Insulin Producing, Osteoblast-Like and Neural Cells. Curr Stem Cell Res Ther. 2019;14(7):570\u20138.","journal-title":"Curr Stem Cell Res Ther"},{"issue":"1","key":"5229_CR233","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3727\/096368912X647162","volume":"22","author":"MM Gabr","year":"2013","unstructured":"Gabr MM, et al. Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice. Cell Transpl. 2013;22(1):133\u201345.","journal-title":"Cell Transpl"},{"issue":"9","key":"5229_CR234","doi-asserted-by":"publisher","first-page":"578","DOI":"10.4252\/wjsc.v11.i9.578","volume":"11","author":"I Mitxitorena","year":"2019","unstructured":"Mitxitorena I, et al. Suitability and limitations of mesenchymal stem cells to elucidate human bone illness. World J Stem Cells. 2019;11(9):578\u201393.","journal-title":"World J Stem Cells"},{"issue":"5","key":"5229_CR235","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/jcmm.12036","volume":"17","author":"JL Carvalho","year":"2013","unstructured":"Carvalho JL, et al. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med. 2013;17(5):617\u201325.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"5229_CR236","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-019-1224-y","volume":"10","author":"NC Noronha","year":"2019","unstructured":"Noronha NC, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10(1):131.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR237","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2018.01.002","volume":"28","author":"DS Kim","year":"2018","unstructured":"Kim DS, et al. Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-\u03b3. EBioMedicine. 2018;28:261\u201373.","journal-title":"EBioMedicine"},{"issue":"2","key":"5229_CR238","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.61.2.6","volume":"61","author":"B Mead","year":"2020","unstructured":"Mead B, et al. TNF\u03b1-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells. Invest Ophthalmol Vis Sci. 2020;61(2):6.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5229_CR239","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2001-1326-3-21","volume":"3","author":"Y Gothelf","year":"2014","unstructured":"Gothelf Y, et al. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin Transl Med. 2014;3:21.","journal-title":"Clin Transl Med"},{"issue":"10","key":"5229_CR240","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/sctm.16-0485","volume":"6","author":"AJ Guess","year":"2017","unstructured":"Guess AJ, et al. Safety Profile of Good Manufacturing Practice Manufactured Interferon \u03b3-Primed Mesenchymal Stem\/Stromal Cells for Clinical Trials. Stem Cells Transl Med. 2017;6(10):1868\u201379.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"5229_CR241","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-019-0723-8","volume":"12","author":"Y Yang","year":"2019","unstructured":"Yang Y, et al. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells. J Hematol Oncol. 2019;12(1):46.","journal-title":"J Hematol Oncol"},{"key":"5229_CR242","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijcard.2015.08.117","volume":"201","author":"SC Suresh","year":"2015","unstructured":"Suresh SC, et al. Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium. Int J Cardiol. 2015;201:517\u201328.","journal-title":"Int J Cardiol"},{"issue":"2","key":"5229_CR243","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2009.08.031","volume":"290","author":"P Gao","year":"2010","unstructured":"Gao P, et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 2010;290(2):157\u201366.","journal-title":"Cancer Lett"},{"issue":"4","key":"5229_CR244","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3892\/etm.2014.1918","volume":"8","author":"J Han","year":"2014","unstructured":"Han J, et al. Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med. 2014;8(4):1330\u20134.","journal-title":"Exp Ther Med"},{"issue":"6","key":"5229_CR245","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/stem.2801","volume":"36","author":"T Relation","year":"2018","unstructured":"Relation T, et al. Intratumoral Delivery of Interferon\u03b3-Secreting Mesenchymal Stromal Cells Repolarizes Tumor-Associated Macrophages and Suppresses Neuroblastoma Proliferation In Vivo. Stem Cells. 2018;36(6):915\u201324.","journal-title":"Stem Cells"},{"issue":"5","key":"5229_CR246","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/gt.2010.170","volume":"18","author":"SH Seo","year":"2011","unstructured":"Seo SH, et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 2011;18(5):488\u201395.","journal-title":"Gene Ther"},{"issue":"1","key":"5229_CR247","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13287-017-0511-8","volume":"8","author":"D Gerace","year":"2017","unstructured":"Gerace D, et al. CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Res Ther. 2017;8(1):62.","journal-title":"Stem Cell Res Ther"},{"key":"5229_CR248","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/5584_2019_459","volume":"1247","author":"A Golchin","year":"2020","unstructured":"Golchin A, Shams F, Karami F. Advancing Mesenchymal Stem Cell Therapy with CRISPR\/Cas9 for Clinical Trial Studies. Adv Exp Med Biol. 2020;1247:89\u2013100.","journal-title":"Adv Exp Med Biol"},{"key":"5229_CR249","doi-asserted-by":"crossref","unstructured":"Miwa H, Era T. Tracing the destiny of mesenchymal stem cells from embryo to adult bone marrow and white adipose tissue via Pdgfr\u03b1 expression. Development. 2018;145(2):dev155879.","DOI":"10.1242\/dev.155879"},{"issue":"6","key":"5229_CR250","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/ijc.32230","volume":"145","author":"JC von Einem","year":"2019","unstructured":"von Einem JC, et al. Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1\/2 TREAT-ME-1 trial. Int J Cancer. 2019;145(6):1538\u201346.","journal-title":"Int J Cancer"},{"issue":"6","key":"5229_CR251","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.stemcr.2016.05.003","volume":"6","author":"SH Ranganath","year":"2016","unstructured":"Ranganath SH, et al. Controlled Inhibition of the Mesenchymal Stromal Cell Pro-inflammatory Secretome via Microparticle Engineering. Stem Cell Rep. 2016;6(6):926\u201339.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"5229_CR252","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","volume":"10","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. J Hematol Oncol. 2017;10(1):56.","journal-title":"J Hematol Oncol"},{"key":"5229_CR253","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1038\/srep04645","volume":"4","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, et al. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. Sci Rep. 2014;4:4645.","journal-title":"Sci Rep"},{"issue":"11","key":"5229_CR254","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1161\/CIRCRESAHA.116.310374","volume":"120","author":"L Luo","year":"2017","unstructured":"Luo L, et al. Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice. Circ Res. 2017;120(11):1768\u201375.","journal-title":"Circ Res"},{"key":"5229_CR255","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.biomaterials.2014.10.028","volume":"37","author":"G Vall\u00e9s","year":"2015","unstructured":"Vall\u00e9s G, et al. Topographical cues regulate the crosstalk between MSCs and macrophages. Biomaterials. 2015;37:124\u201333.","journal-title":"Biomaterials"},{"issue":"12","key":"5229_CR256","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.7150\/thno.83066","volume":"13","author":"CP Palanisamy","year":"2023","unstructured":"Palanisamy CP, et al. New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs). Theranostics. 2023;13(12):4138\u201365.","journal-title":"Theranostics"},{"key":"5229_CR257","doi-asserted-by":"crossref","unstructured":"Li S et al. Mesenchymal stem cell-derived extracellular vesicles: current advances in preparation and therapeutic applications for neurological disorders. Front Cell Dev Biol. 2025;13\u20132025:1626996 .","DOI":"10.3389\/fcell.2025.1626996"},{"issue":"4","key":"5229_CR258","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/jgh.16110","volume":"38","author":"H Pak","year":"2023","unstructured":"Pak H, et al. Safety and efficacy of injection of human placenta mesenchymal stem cells derived exosomes for treatment of complex perianal fistula in non-Crohn\u2019s cases: Clinical trial phase I. J Gastroenterol Hepatol. 2023;38(4):539\u201347.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"5229_CR259","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s13287-025-04690-y","volume":"16","author":"MS Kishta","year":"2025","unstructured":"Kishta MS, et al. The transforming role of wharton\u2019s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Res Ther. 2025;16(1):559.","journal-title":"Stem Cell Res Ther"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05229-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:01:58Z","timestamp":1787072518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":259,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5229"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05229-5","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"12 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"285"}}